Results 211 to 220 of about 8,187 (238)
Some of the next articles are maybe not open access.
Catecholate Siderophore Receptor CirA Impacts Cefiderocol Susceptibility in Klebsiella pneumoniae
International Journal of Antimicrobial Agents, 2022Xueqing Wu, Lan Peng, Jian-Cang Zhou
exaly
2017
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shio nogi alone. By virtue of in vitro activity against carbapenem- resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC ...
openaire +2 more sources
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shio nogi alone. By virtue of in vitro activity against carbapenem- resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC ...
openaire +2 more sources

